<SEC-DOCUMENT>0001387131-18-002408.txt : 20180530
<SEC-HEADER>0001387131-18-002408.hdr.sgml : 20180530
<ACCEPTANCE-DATETIME>20180530060158
ACCESSION NUMBER:		0001387131-18-002408
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180530
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180530
DATE AS OF CHANGE:		20180530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		18866441

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_053018.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_Hlk512950810"></A></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">FORM
8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Date of Report (Date of earliest event
reported): May 30, 2018</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TherapeuticsMD, Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Registrant&#8217;s telephone number,
including area code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-bottom: 12pt; text-align: justify">&#9744;</TD>
    <TD STYLE="padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&#9744;</TD>
    <TD STYLE="padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to </FONT><A NAME="a_9kR3WTr277457Za1m3Hr2ICBvn2I9vThCxw3A2X"></A><FONT STYLE="font-size: 10pt">Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&#9744;</TD>
    <TD STYLE="padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under
    the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Emerging growth company&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">On May 30, 2018,
TherapeuticsMD, Inc., a Nevada corporation (the &#8220;<U>Company</U>&#8221;), issued a press release announcing that the Company
received approval from the U.S. Food and Drug Administration (FDA) for the Company&#8217;s New Drug Application (NDA) for TX-004HR:
IMVEXXY<SUP>TM</SUP> (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with
sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. A copy of the press release is furnished as
Exhibit&nbsp;99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included
in this Item 7.01 and in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended (the &#8220;<U>Exchange Act</U>&#8221;), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0; padding-left: 0; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><I>Exhibits</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0; padding-left: 0; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1.5in; padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Exhibit</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><U>Number</U></FONT></P></TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><U>Description </U></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">99.1</FONT></P></TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Press Release from TherapeuticsMD,
        Inc., dated May 30, 2018.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;May 30, 2018</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title</FONT><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 32pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 32pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-8k_053018.htm">TherapeuticsMD, Inc. 8-K</A></FONT></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: right"><IMG SRC="ex99-1_logo.jpg" ALT="" STYLE="height: 28px; width: 239px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>TherapeuticsMD Announces FDA
Approval of TX-004HR: IMVEXXY<SUP>TM</SUP> (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the
Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center"><I>-IMVEXXY&rsquo;s applicator-free
self-administration was developed with the woman in mind-</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><I>-TherapeuticsMD will host a conference
call at 8:00 AM EDT today-</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>BOCA RATON, Fla.--(BUSINESS
WIRE)&mdash;May 30, 2018&mdash;</B>TherapeuticsMD, Inc.&nbsp;(NASDAQ: TXMD), an innovative women&rsquo;s healthcare company, today
announced&nbsp;that the United States Food and Drug Administration (FDA) has approved IMVEXXY<SUP>TM</SUP> (estradiol vaginal inserts)
for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal
atrophy (VVA), due to menopause. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg
representing the lowest approved dose of vaginal estradiol available.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&ldquo;IMVEXXY is a bio-identical
vaginal estrogen product that offers a fraction of the estrogen contained in the average doses of many existing products currently
on the market,&rdquo; said&nbsp;Brian Bernick, MD, Chief Clinical Officer of TherapeuticsMD. &ldquo;IMVEXXY is the only product
specifically designed to be applicator-free. It dissolves completely without mess or additional clean-up, and can be used anytime
of day. It allows women the freedom to immediately return to their normal daily activities. Studies showed that, in patients who
used IMVEXXY, systemic absorption of estradiol remained within postmenopausal range.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&ldquo;We are excited to bring
IMVEXXY to market as TherapeuticsMD&rsquo;s first FDA-approved drug as we strive to be the premier Women&rsquo;s Health Company,&rdquo;
said Robert Finizio, Chief Executive Officer of TherapeuticsMD. &ldquo;IMVEXXY reflects our long-standing corporate mission and
commitment to health solutions that women want, based on the concepts of medical need, efficacy, safety, simplicity, and affordability.
IMVEXXY will be offered at a price in parity with other products that have been on the market for 10 to 30 years. By ensuring patients
can access IMVEXXY at an affordable price, TherapeuticsMD is doing the right thing for women.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>About Dyspareunia and Vulvar and Vaginal Atrophy
(VVA)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">VVA is a component of genitourinary
syndrome of menopause (GSM), which may include, but is not limited to, genital symptoms of dryness, burning and irritation, sexual
symptoms such as decreased lubrication, discomfort, and pain, and urinary symptoms such as urgency, dysuria, and recurrent urinary
tract infections.<SUP>1</SUP> VVA is a chronic, progressive condition that leads to distressing symptoms and can progressively
worsen if not treated.<SUP>2</SUP></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">VVA is a condition that develops
when the body makes less estrogen due to menopause. Without sufficient estrogen, the vaginal tissue becomes thin, dry, and less
elastic. The vaginal canal can also narrow and shorten. Insufficient estrogen can also decrease vaginal fluids, change the acid
balance of the vagina, and weaken pelvic floor muscles. All these factors can lead to dyspareunia.<SUP>2</SUP></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">VVA affects an estimated 32 million
postmenopausal women in the US. Only about seven percent (2.3 million) of these women receive prescription treatment.<SUP>3 </SUP>
Nearly 1 out of 2 women will experience pain during intercourse due to VVA at some point during their lives.<SUP>3</SUP></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&ldquo;Studies have shown that
many women are not seeking treatment for VVA and 81% are unaware that VVA is a treatable medical condition and part of a constellation
of symptoms associated with loss of estrogens,&quot; said Dr. Sheryl Kingsberg, President, North American Menopause Society. &quot;I
am delighted that our patients will now have a convenient treatment option with IMVEXXY and hope that the excitement generated
by this new option will encourage women to talk to their healthcare provider and get relief from their pain and discomfort due
to VVA.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>IMVEXXY For the Treatment of Moderate to Severe
Dyspareunia Due to Menopause</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Imvexxy&rsquo;s mechanism of action
is the re-estrogenization of the tissue in and around the vagina. IMVEXXY&rsquo;s distinctive formulation ensures that it dissolves
completely without mess, so patients can use it any time of day by placing the softgel capsule in the lower part of the vagina
to treat the vulva and vagina. IMVEXXY is administered daily for two weeks followed by only twice a week dosing. Nine out of 10
patients who participated in a clinical trial reported that IMVEXXY was &ldquo;easy to use.&rdquo;<A NAME="a_Hlk504047114"></A><SUP>4</SUP></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The FDA approval of IMVEXXY is
based on the results of a Phase 3, randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of
IMVEXXY (4 mcg and 10 mcg) compared to placebo from baseline to week 12. The study showed that IMVEXXY provided relief of moderate
to severe dyspareunia due to menopause as early as week 2 for both doses.<SUP>5</SUP> Statistically significant changes in vaginal
cytology and pH were also observed.<SUP>5</SUP> <A NAME="a_Hlk515023766"></A>A substudy of the REJOICE trial evaluated the pharmacokinetics
of IMVEXXY 4 mcg, 10 mcg, and placebo. With both the 4 mcg and 10 mcg doses, the mean concentration of estradiol and estrone remained
within average postmenopausal range.<SUP>6</SUP> The results were published in the journal <I>Menopause: The Journal of The North
American Menopause Society</I>.<SUP>5,6</SUP></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The most common adverse reaction
with IMVEXXY (incidence &#8805;3 percent) and greater than placebo was headache. There were no clinically significant differences
in AEs observed between treatment and placebo groups.<SUP>5</SUP> Important safety information for IMVEXXY, including the boxed
warning for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, is provided below. The full prescribing
information may be viewed by visiting www.imvexxy.com.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">TherapeuticsMD anticipates that IMVEXXY will be available
for commercial distribution in July.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the FDA&rsquo;s approval,
TherapeuticsMD has committed to conduct a post-approval observational study.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Conference Call Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">TherapeuticsMD will host a conference call today to discuss
the IMVEXXY approval. Details for the call are:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 50%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wednesday, May 30, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time:</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8:00 AM EDT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone Access (US):</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(866) 665-9531</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone Access (International): </FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(724) 987-6977</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access Code for All Callers:</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4757309</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, a live webcast can be
accessed on the company&rsquo;s website, www.therapeuticsmd.com, on the Home Page or under the &ldquo;Investors &amp; Media&rdquo;
section. A digital recording of the conference call will be available for replay beginning two hours after the call's completion
and for at least 30 days with the dial-in (855) 859-2056 or international (404) 537-3406 and Conference ID: 4757309.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR
        DISORDERS, BREAST CANCER and PROBABLE DEMENTIA</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B><I>See full prescribing information
        for complete boxed warning.</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.4pt"><B><U>Estrogen-Alone Therapy</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>There
        is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>Estrogen-alone
        therapy should not be used for the prevention of cardiovascular disease or dementia </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>The
        Women&#146;s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
        </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>The
        WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal
        women 65 years of age and older </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.4pt"><B><U>Estrogen Plus Progestin Therapy</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>Estrogen
        plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>The
        WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE) and myocardial infarction
        (MI) </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>The
        WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 18.25pt; text-indent: -7.85pt">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.25pt"><B>The
        WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65
        years of age and older</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CONTRAINDICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMVEXXY&trade;&nbsp;&nbsp;is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to IMVEXXY; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>WARNINGS AND PRECAUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMVEXXY is intended only for vaginal administration. Systemic absorption may occur with the use of IMVEXXY.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other warnings include: gallbladder disease; severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Women on thyroid replacement therapy should have their thyroid function monitored.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ADVERSE REACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The most common adverse reaction with IMVEXXY (incidence &#8805; 3&nbsp;percent) and greater than placebo was headache.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt"><B>Please note that this information is not comprehensive.
Please visit www.imvexxy.com for the <U>Full Prescribing Information</U>, including the Boxed Warning.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>About&nbsp;TherapeuticsMD, Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">TherapeuticsMD, Inc.&nbsp;is an
innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade;
technology,&nbsp;TherapeuticsMD&nbsp;is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes. The company has recently received FDA approval for TX-004HR,
branded as IMVEXXY&trade; (estradiol vaginal inserts), for the treatment of moderate to severe dyspareunia, a symptom of vulvar
and vaginal atrophy, due to menopause. The company&rsquo;s late stage clinical pipeline includes TX-001HR for treatment of moderate-to-severe
vasomotor symptoms (VMS) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal
vitamins as well as over-the-counter prenatal vitamins under the vitaMedMD&reg;&nbsp;and BocaGreenMD&reg;&nbsp;brands.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">This press release by&nbsp;TherapeuticsMD,
Inc.&nbsp;may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions and
assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the&nbsp;Securities and Exchange Commission, including its
most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
whether the FDA will approve the NDA for the company&rsquo;s TX-001HR product candidate and whether such approval will occur by
the PDUFA target action date; the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s ability
to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the
company be able to comply with the covenants and conditions under its term loan agreement; the length, cost and uncertain results
of the company&rsquo;s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval
of the company&rsquo;s hormone therapy drug candidates; the company&rsquo;s reliance on third parties to conduct its clinical trials,
research and development and manufacturing; the availability of reimbursement from government authorities and health insurance
companies for the company&rsquo;s products; the impact of product liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company&rsquo;s common stock and the concentration of power in its stock
ownership. PDF copies of the company&rsquo;s historical press releases and financial tables can be viewed and downloaded at its
website:&nbsp;www.therapeuticsmd.com/pressreleases.aspx.</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>CONTACTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Nichol Ochsner,</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Vice President Investor Relations</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">561-961-1900, ext. 2088</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Nochsner@TherapeuticsMD.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Heidi Lorman,</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Senior Vice President, Health</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Zeno Group</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">646-239-1237</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Heidi.Lorman@zenogroup.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>References:</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women&rsquo;s Sexual Health and the North American Menopause Society. <I>Menopause</I>. 2014;21(10):1063-1068.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. <I>Menopause</I>. 2013;20(9):888&ndash;902.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. <I>Clin Med Insights Reprod Health</I>. 2014;8:23-30. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kingsberg SA, Kroll R, Goldstein I, et al. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. <I>Menopause.</I> 2017;24:894-899. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. <I>Menopause</I>. 2017;24:409-416.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Archer DF, Constantine GD, Simon J, et al.TX-004HR Vaginal Estradiol Has Negligible to Very Low Systemic Absorption of Estradiol. Menopause 2017;24:510-516.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"># # #</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < .\# 2(  A$! Q$!_\0
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M)\Y_+ VY].:H6'CK4=#L4TW7_"6HR:A;H(Q+;0ATFQP&S[^V?Z5ZC14>UO\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
